Prostate cancer
CRPC: treatment in daily clinical practice

Anthony (58 years old)

Anthony, a 58-year-old police officer, was diagnosed with multiple bone metastatic PCa (PSA 385 ng/ml) almost 3 years ago. He has no major comorbidities.

Course of the disease:

  • Treatment with ADT + 6 cycles of docetaxel. His PSA 6 months after starting chemohormonal therapy was 2.1 ng/ml, ALP 31 U/l
  • At 24 months post-ADT initiation:
    • Increase in PSA to 24 ng/ml in 8 months
    • Castrate testosterone level
    • Bone scan: progression of bone metastases
    • CT scan: 1 visceral metastasis (lung)
    • Bone pain: requires paracetamol
    • ECOG PS: 1
  • Treatment for mCRPC was started with abiraterone:
    • PSA: 4.1 ng/ml
    • Bone metastases shrank by 20% (RECIST)
  • Now, 9 months after starting abiraterone:
    • PSA: 20 ng/ml, ALP: 185 U/l
    • CT scan: radiographic progression of lymph nodes and lung metastasis (new)
    • ECOG PS: 1
    • No germline and/or somatic BRCA1/2 mutation identified

Which treatment option would you choose for this patient?